-
Who we are
Who we are
Novavax is a global biotechnology company with a proven vaccine technology. We are focused on developing our R&D assets and establishing partnerships to leverage the value of our technology to help protect health.
Discover our scienceLearn about our validated protein-based nanoparticle and Matrix-M™ adjuvant technology.
-
What we do
What we do
Novavax is focused on using our proven vaccine technology to help protect health through the development of our R&D assets and establishing partnerships
Latest UpdatesStay current with Novavax news as we make progress in discovering and developing innovative vaccines to help protect against serious infectious diseases.
-
Blog
Blog
Novavax is committed to accelerating the development of new and promising vaccines and sharing information based on years of study and experience.
Rick Rodgers, MBA
Director
Mr. Rodgers joined the Novavax board of directors in 2022. From 2010 to 2013, he was co-founder, Executive Vice President, Chief Financial Officer, Secretary, and Treasurer of TESARO, Inc., a biopharmaceutical company that was acquired in January 2019 by GSK. From 2009 to 2010, Mr. Rodgers served as the Chief Financial Officer and Senior Vice President of Abraxis BioScience, Inc., a biotechnology company that was acquired by Celgene. From 2004 to 2008, he served as Senior Vice President, Controller and Chief Accounting Officer of MGI PHARMA, Inc., a biopharmaceutical company that was acquired in January 2008 by Eisai. Mr. Rodgers currently serves on the boards of directors and as the chair of the audit committee and member of the compensation committee of Ocuphire Pharma, Inc., Sagimet Biosciences, Inc., and Ardelyx, Inc. Mr. Rodgers holds a Bachelor of Science degree in Financial Accounting from St. Cloud State University and a Master of Business Administration in Finance from the University of Minnesota, Carlson School of Business.